LabCorp (NYSE:LH), along with a main rival, control a high percentage of the domestic lab testing market. One would think this dominance would translate into solid growth potential, but challenging industry conditions could keep overall growth constrained going forward.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

First Quarter Recap
Revenues advanced 4% to $1.4 billion. Management attributed the increase to 2.8 percentage points of volume increases and 1.2 percentage points of higher pricing, or revenue per requisition. About 41% of LabCorp's tests stemmed from higher margin genomic, esoteric and related revenue. It has a goal to boost this to 45% of sales within the next five years.

Cost controls helped send operating income up by nearly 22% to $287.1 million. This represented a solid operating margin of 20.5% of revenues. Lower interest expense helped send net income up by 27.1% to $161.6 million, or $1.63 per diluted share. Backing out some costs management felt were not recurring or reflective of its underlying operations, adjusted earnings were $1.74 per diluted share and up 14.4% from last year's first quarter. Free cash flow declined 12.4% to $162.9 million to slightly exceed reported income.

SEE: Understanding The Income Statement

Outlook and Valuation
For the full year, LabCorp said to expect revenue growth of between 2 and 3.5%. Analysts currently project top line growth of about 3% and total revenues just shy of $6 billion. Looking at the competitive landscape, Quest Diagnostics (NYSE:DGX) will log a similar level of sales growth and total sales of nearly $8 billion. Smaller rivals include Bio-Reference Labs (Nasdaq:BRLI) and Medtox (Nasdaq:MTOX), both of which are projected to report double-digit sales growth and total sales of $662 million and $119 million, respectively.

The company projects adjusted earnings in a range of $6.75 and $7.05 per share and free cash flow of almost $800 million, or approximately $8 per diluted share. At the current share price of $86.91, the forward P/E is 11.5 and forward free cash flow multiple is 11.

The Bottom Line
LabCorp pegs the total U.S. lab testing market at $55 billion, giving it a market share of above 10%. Combined with Quest, these two largest players control a quarter of the market. Hospitals including HMA (NYSE:HMA) and HCA (NYSE:HCA) collectively dominate most of the rest of the market.

The consolidated market is making it difficult for LabCorp to grow as rapidly as it once was. Additionally, it is feeling pressures from large health insurers and the government, both of which are using their clout to drive down pricing. These tough operating conditions will likely keep growth constrained, but LabCorp remains firmly profitable and a generator of tons of annual free cash flow.

SEE: 5 Must-Have Metrics For Value Investors

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Ryan C. Fuhrmann did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  3. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  4. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  5. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  6. Stock Analysis

    The Top 5 Micro Cap Biotechnology Stocks for 2016 (BSTC, OSIR)

    Discover some of the most promising micro-cap biotechnology stocks that investors can consider for their 2016 investment portfolio.
  7. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  8. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  9. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  10. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center